Medtronic to Acquire SPR Therapeutics for $650 Million
Medtronic will buy SPR Therapeutics for $650 million to expand its pain portfolio. The deal adds a non-permanent implant system to its medical product range.
Xurve View
Insights:
Xurve View
MEDTRONIC PLC will acquire privately held SPR Therapeutics for approximately $650 million in cash to expand its chronic pain portfolio. The deal provides the medical device leader with a non-permanent, 60-day therapy system designed for minimally invasive pain relief. This acquisition allows Medtronic to capture market share in the growing non-opioid, non-surgical treatment sector.
